Starling Oncology, Inc. (STLN) Total liabilities 2020–2025
Starling Oncology, Inc. (STLN) total liabilities at each fiscal year-end, per SEC filings.
$180.4MFY2025 · since FY2020: $37.6M → $180.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $180.4M | +6.7% |
| FY2024 | $169.1M | +11.1% |
| FY2023 | $152.2M | +9.9% |
| FY2022 | $138.5M | +39.5% |
| FY2021 | $99.3M | +164.1% |
| FY2020 | $37.6M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More STLN financial trends
STLN RevenueSTLN Net incomeSTLN Net marginSTLN Gross profitSTLN Gross marginSTLN Operating incomeSTLN Operating marginSTLN Operating cash flowSTLN Free cash flowSTLN Capital expendituresSTLN Return on equitySTLN Stock buybacksSTLN Dividends paidSTLN Total assetsSTLN Shareholders’ equitySTLN overview →